146 related articles for article (PubMed ID: 36316840)
1. Effect of metformin on nonalcoholic fatty liver based on meta-analysis and network pharmacology.
Huang Y; Wang X; Yan C; Li C; Zhang L; Zhang L; Liang E; Liu T; Mao J
Medicine (Baltimore); 2022 Oct; 101(43):e31437. PubMed ID: 36316840
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Metformin on Aminotransferase Levels, Metabolic Parameters and Body Mass Index in Nonalcoholic Fatty Liver Disease Patients: A Metaanalysis.
Hu H; Wang J; Li X; Shen L; Shi D; Meng J
Curr Pharm Des; 2021; 27(29):3235-3243. PubMed ID: 33719959
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
5. The clinical effect of probiotics on patients with non-alcoholic fatty liver disease: a meta-analysis.
Wang Y; Wang Y; Sun J
Bioengineered; 2022; 13(7-12):14960-14973. PubMed ID: 37105767
[TBL] [Abstract][Full Text] [Related]
6. [Correlation analysis of gut microbiota and biochemical indexes in patients with non-alcoholic fatty liver disease].
Ren SM; Mei L; Huang H; Cao SF; Zhao RH; Zheng PY
Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):369-375. PubMed ID: 31177662
[No Abstract] [Full Text] [Related]
7. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
[No Abstract] [Full Text] [Related]
8. [Effect of metformin on the expression of SIRT1 and UCP2 in rat liver of type 2 diabetes mellitus and nonalcoholic fatty liver].
Xu J; Li N; Wang J; Zhang C; Ding S; Jiao Y; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Sep; 38(9):882-7. PubMed ID: 24071688
[TBL] [Abstract][Full Text] [Related]
9. Serum phospholipid omega-3 polyunsaturated fatty acids and insulin resistance in type 2 diabetes mellitus and non-alcoholic fatty liver disease.
Lou DJ; Zhu QQ; Si XW; Guan LL; You QY; Yu ZM; Zhang AZ
J Diabetes Complications; 2014; 28(5):711-4. PubMed ID: 24927647
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
Front Immunol; 2022; 13():949746. PubMed ID: 36159792
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of liraglutide in treating type 2 diabetes mellitus complicated with non-alcoholic fatty liver disease.
Tian F; Zheng Z; Zhang D; He S; Shen J
Biosci Rep; 2018 Dec; 38(6):. PubMed ID: 30473540
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Effect of Metformin on Chemerin in Non-Obese Patients with Non-Alcoholic Fatty Liver Disease (NAFLD).
Zhuang X; Sun F; Li L; Jiang D; Li X; Sun A; Pan Z; Lou N; Zhang L; Lou F
Clin Lab; 2015; 61(10):1409-14. PubMed ID: 26642701
[TBL] [Abstract][Full Text] [Related]
13. Exploring the active compounds and potential mechanism of the anti-nonalcoholic fatty liver disease activity of the fraction from Schisandra chinensis fruit extract based on multi-technology integrated network pharmacology.
Li B; Xiao Q; Zhang J; Wang Y; Liu J; Zhang B; Liu H
J Ethnopharmacol; 2023 Jan; 301():115769. PubMed ID: 36183952
[TBL] [Abstract][Full Text] [Related]
14. Association between resistin +299A/A genotype and nonalcoholic fatty liver disease in Chinese patients with type 2 diabetes mellitus.
Zhang LY; Jin YJ; Jin QS; Lin LY; Zhang DD; Kong LL
Gene; 2013 Oct; 529(2):340-4. PubMed ID: 23954219
[TBL] [Abstract][Full Text] [Related]
15. [Analysis of metabolic risk factors for developing nonalcoholic fatty liver in patients with type 2 diabetes mellitus].
Guo M; Xi G; Yang N; Yao H
Zhonghua Gan Zang Bing Za Zhi; 2014 Aug; 22(8):631-5. PubMed ID: 25243967
[TBL] [Abstract][Full Text] [Related]
16. Association between Thyroid Function and Nonalcoholic Fatty Liver Disease in Euthyroid Type 2 Diabetes Patients.
Huang B; Yang S; Ye S
J Diabetes Res; 2020; 2020():6538208. PubMed ID: 32964054
[TBL] [Abstract][Full Text] [Related]
17. Effects of sitagliptin on intrahepatic lipid content in patients with non-alcoholic fatty liver disease.
Wang X; Zhao B; Sun H; You H; Qu S
Front Endocrinol (Lausanne); 2022; 13():866189. PubMed ID: 36072931
[TBL] [Abstract][Full Text] [Related]
18. Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis.
Ma YY; Li L; Yu CH; Shen Z; Chen LH; Li YM
World J Gastroenterol; 2013 Oct; 19(40):6911-8. PubMed ID: 24187469
[TBL] [Abstract][Full Text] [Related]
19. Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Li Y; Liu L; Wang B; Wang J; Chen D
Biomed Rep; 2013 Jan; 1(1):57-64. PubMed ID: 24648894
[TBL] [Abstract][Full Text] [Related]
20. The benefit of metformin in the treatment of pediatric non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials.
Gkiourtzis N; Michou P; Moutafi M; Glava A; Cheirakis K; Christakopoulos A; Vouksinou E; Fotoulaki M
Eur J Pediatr; 2023 Nov; 182(11):4795-4806. PubMed ID: 37639015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
